FRA:SRT3

Sartorius Aktiengesellschaft Competitors

€462.50
+6.40 (+1.40 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
€454.40
Now: €462.50
€466.00
50-Day Range
€398.00
MA: €432.24
€469.80
52-Week Range
€71.00
Now: €462.50
€124.70
Volume60,040 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Sartorius Aktiengesellschaft (FRA:SRT3) Vs. AGN, AMS, BAYN, DIA, EI, and FRE

Should you be buying SRT3 stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Sartorius Aktiengesellschaft, including AEGON (AGN), American Shared Hospital Services (AMS), Bayer Aktiengesellschaft (BAYN), DiaSorin (DIA), Essilor International Société Anonyme (EI), and Fresenius SE & Co. KGaA (FRE).

Sartorius Aktiengesellschaft (FRA:SRT3) and AEGON (AMS:AGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Sartorius Aktiengesellschaft and AEGON's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sartorius AktiengesellschaftN/AN/AN/A
AEGONN/AN/AN/A

Valuation and Earnings

This table compares Sartorius Aktiengesellschaft and AEGON's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A
AEGONN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sartorius Aktiengesellschaft and AEGON, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sartorius Aktiengesellschaft16202.11
AEGON0000N/A

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%.

Summary

Sartorius Aktiengesellschaft beats AEGON on 1 of the 1 factors compared between the two stocks.

Sartorius Aktiengesellschaft (FRA:SRT3) and American Shared Hospital Services (BME:AMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Valuation & Earnings

This table compares Sartorius Aktiengesellschaft and American Shared Hospital Services' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A
American Shared Hospital ServicesN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sartorius Aktiengesellschaft and American Shared Hospital Services, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sartorius Aktiengesellschaft16202.11
American Shared Hospital Services0000N/A

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%.

Profitability

This table compares Sartorius Aktiengesellschaft and American Shared Hospital Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sartorius AktiengesellschaftN/AN/AN/A
American Shared Hospital ServicesN/AN/AN/A

Summary

Sartorius Aktiengesellschaft beats American Shared Hospital Services on 1 of the 1 factors compared between the two stocks.

Sartorius Aktiengesellschaft (FRA:SRT3) and Bayer Aktiengesellschaft (FRA:BAYN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sartorius Aktiengesellschaft16202.11
Bayer Aktiengesellschaft051102.69

Sartorius Aktiengesellschaft presently has a consensus target price of €321.89, indicating a potential downside of 30.40%. Bayer Aktiengesellschaft has a consensus target price of €69.93, indicating a potential upside of 25.58%. Given Bayer Aktiengesellschaft's stronger consensus rating and higher possible upside, analysts plainly believe Bayer Aktiengesellschaft is more favorable than Sartorius Aktiengesellschaft.

Valuation & Earnings

This table compares Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A
Bayer AktiengesellschaftN/AN/AN/AN/AN/A

Profitability

This table compares Sartorius Aktiengesellschaft and Bayer Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sartorius AktiengesellschaftN/AN/AN/A
Bayer AktiengesellschaftN/AN/AN/A

Summary

Bayer Aktiengesellschaft beats Sartorius Aktiengesellschaft on 3 of the 3 factors compared between the two stocks.

DiaSorin (BIT:DIA) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares DiaSorin and Sartorius Aktiengesellschaft's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorinN/AN/AN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Sartorius Aktiengesellschaft, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin0000N/A
Sartorius Aktiengesellschaft16202.11

Sartorius Aktiengesellschaft has a consensus target price of €321.89, suggesting a potential downside of 30.40%.

Profitability

This table compares DiaSorin and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/A

Summary

Sartorius Aktiengesellschaft beats DiaSorin on 1 of the 1 factors compared between the two stocks.

Essilor International Société Anonyme (EPA:EI) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Essilor International Société Anonyme and Sartorius Aktiengesellschaft's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Essilor International Société AnonymeN/AN/AN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A

Profitability

This table compares Essilor International Société Anonyme and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Essilor International Société AnonymeN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Essilor International Société Anonyme and Sartorius Aktiengesellschaft, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Essilor International Société Anonyme0000N/A
Sartorius Aktiengesellschaft16202.11

Sartorius Aktiengesellschaft has a consensus price target of €321.89, suggesting a potential downside of 30.40%. Given Sartorius Aktiengesellschaft's higher probable upside, analysts plainly believe Sartorius Aktiengesellschaft is more favorable than Essilor International Société Anonyme.

Summary

Sartorius Aktiengesellschaft beats Essilor International Société Anonyme on 2 of the 2 factors compared between the two stocks.

Fresenius SE & Co. KGaA (FRA:FRE) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius SE & Co. KGaAN/AN/AN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/AN/AN/A

Profitability

This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius SE & Co. KGaAN/AN/AN/A
Sartorius AktiengesellschaftN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius SE & Co. KGaA131102.67
Sartorius Aktiengesellschaft16202.11

Fresenius SE & Co. KGaA presently has a consensus target price of €46.07, suggesting a potential upside of 15.69%. Sartorius Aktiengesellschaft has a consensus target price of €321.89, suggesting a potential downside of 30.40%. Given Fresenius SE & Co. KGaA's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fresenius SE & Co. KGaA is more favorable than Sartorius Aktiengesellschaft.

Summary

Fresenius SE & Co. KGaA beats Sartorius Aktiengesellschaft on 3 of the 3 factors compared between the two stocks.


Sartorius Aktiengesellschaft Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AEGON logo
AGN
AEGON
0.5N/AN/A$0.00N/A0.00Gap Down
AMS
American Shared Hospital Services
0.5N/AN/A$0.00N/A0.00Gap Down
Bayer Aktiengesellschaft logo
BAYN
Bayer Aktiengesellschaft
1.3$55.69+0.3%$0.00N/A0.00
DIA
DiaSorin
0.6N/AN/A$0.00N/A0.00Gap Down
Essilor International Société Anonyme logo
EI
Essilor International Société Anonyme
0.5$126.85+0.0%$0.00N/A0.00
Fresenius SE & Co. KGaA logo
FRE
Fresenius SE & Co. KGaA
1.3$39.82+1.0%$0.00N/A0.00
GNFT
Genfit
0.5$3.72+0.8%$0.00N/A0.00High Trading Volume
MERCK Kommanditgesellschaft auf Aktien logo
MRK
MERCK Kommanditgesellschaft auf Aktien
0.7$144.50+0.6%$0.00N/A0.00
Novan logo
NOVN
Novan
0.4N/AN/A$0.00N/A0.00News Coverage
Gap Down
Sanofi logo
SAN
Sanofi
1.1$86.55+0.3%$0.00N/A0.00
Sartorius Stedim Biotech logo
DIM
Sartorius Stedim Biotech
0.8$388.90+0.9%$0.00N/A0.00High Trading Volume
STADA Arzneimittel Aktiengesellschaft logo
SAZ
STADA Arzneimittel Aktiengesellschaft
0.4$80.40+0.0%$0.00N/A0.00
TEV
Teva Pharmaceutical Industries
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.